On Friday (22), the National Health Surveillance Agency (Anvisa) approved the update of two vaccines against Covid-19 in Brazil. They are Spikevax, developed by Adium, and Comirnaty, created by Pfizer.
With the new authorized compositions, both immunizers will be able to change the strain used in manufacturing. Anvisa’s most recent recommendation, published on April 26, establishes the need to adapt vaccines against the JN 1 variant. coronavirus – considered of interest and currently dominant in the world, despite being low risk.
This update is also in accordance with the technical note from the World Health Organization (WHO), which suggests periodic modification of doses, as is already the case with immunizations against Influenza.
Click here to read more
1732476560
#Anvisa #approves #update #vaccines #Covid19 #Brazil
How do updates to Covid-19 vaccines, like those for the JN 1 variant, impact public health measures in Brazil?
**Interview with Dr. Ana Sousa, Epidemiologist**
**Interviewer:** Thank you for joining us today, Dr. Sousa. On November 22, Anvisa approved updates to the Spikevax and Comirnaty Covid-19 vaccines to adapt to the new JN 1 variant. What do you think this means for public health in Brazil?
**Dr. Sousa:** Thank you for having me. This approval is a proactive step in maintaining the effectiveness of our vaccination program. Adapting vaccines to address circulating variants helps ensure that we are providing the best possible protection against Covid-19, despite the current low risk associated with the JN 1 variant.
**Interviewer:** The World Health Organization has also recommended periodic updates to vaccines. How crucial is it for countries like Brazil to follow this guidance?
**Dr. Sousa:** It’s extremely important. The WHO’s recommendation aligns with practices used for influenza vaccines, where annual updates are commonplace. By staying in sync with these guidelines, we can ensure our vaccines remain relevant and effective against emerging strains. This ongoing adaptation is vital not just for immediate protection but also for long-term control of the virus.
**Interviewer:** Given that the JN 1 variant is currently dominant but considered low risk, how should the public react to this news regarding the vaccine updates?
**Dr. Sousa:** Public sentiment should balance caution with understanding. While it’s good news that the threat level remains low, the updates signify that health authorities are vigilant and prepared. It’s essential for individuals to stay informed and continue participating in vaccination programs, as these efforts protect not only themselves but also those at higher risk.
**Interviewer:** As we wrap up, what message would you like to share with our readers about vaccine updates and public health?
**Dr. Sousa:** I encourage everyone to view these vaccine updates positively. They illustrate our commitment to adapting our health strategies in response to evolving challenges. I’d love to hear the community’s thoughts on this. Are people feeling reassured by the adaptability of our vaccines, or is there concern about the continuous changes? Public dialog is vital as we navigate this landscape together.
**Interviewer:** Thank you, Dr. Sousa, for your insights. Readers, what do you think about these vaccine updates? Do you feel confident in the vaccine’s ability to keep up with new variants? Share your thoughts with us!
